文献速递头颈部肿瘤放疗放疗物理与技术

局部晚期头颈癌乏氧亚体积剂量递增:基于动态[18F]FMISO PET/CT的随机II期研究

Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT.
PubMed 文献 · Radiother Oncol · 2022-04-05

局部晚期头颈鳞癌患者行基线动态[18F]FMISO PET/CT,乏氧肿瘤患者随机接受标准放疗70Gy/35次或对乏氧体积剂量递增至77Gy/35次,非乏氧肿瘤接受标准放疗。研究因入组缓慢提前终止,共纳入53例,乏氧肿瘤39例(74%)被随机。乏氧肿瘤5年局部控制率74% vs 非乏氧100%(p=0.039);剂量递增组5年局部控制率16/19 vs 标准放疗组10/17,差异25%,p=0.150;两组急性和晚期毒性无相关差异。

要点

  • 乏氧PET对局部晚期头颈癌局部控制有预后价值:乏氧肿瘤5年局部控制率74% vs 非乏氧100%(p=0.039)。
  • 乏氧体积剂量递增至77Gy/35次 vs 标准70Gy/35次,5年局部控制率16/19 vs 10/17,差异25%,p=0.150。
  • 两组急性及晚期毒性无相关差异;研究因入组缓慢提前终止。

核心结论

  • 本研究证实乏氧PET对局部晚期头颈癌局部控制具有预后价值。
  • 乏氧剂量递增后的结局似乎有前景,可能支持剂量递增概念。
  • 入组缓慢和提前终止可能部分源于研究设置高度复杂,未来多中心试验需考虑这一点。

研究设计与样本

  • 随机II期试验,局部晚期头颈癌患者行基线动态[18F]FMISO PET/CT,由动态数据导出乏氧体积。
  • 乏氧肿瘤(HV>0)患者随机接受标准放疗(70Gy/35次)或对乏氧体积剂量递增(77Gy/35次);非乏氧肿瘤患者接受标准放疗。
  • 2009年至2017年共纳入53例,其中39例(74%)为乏氧肿瘤并被随机;研究因入组缓慢提前终止;随访至少2年后分析可行性、急性和晚期毒性及局部控制。

主要发现

  • 非乏氧患者5年局部控制率100% vs 乏氧肿瘤患者74%(p=0.039)。
  • 剂量递增组与标准放疗组5年局部控制率分别为16/19 vs 10/17,差异25%,p=0.150。
  • 两组间急性及晚期毒性未观察到相关差异。

局限性

  • 研究因入组缓慢提前终止。
  • 入组缓慢和提前终止可能部分源于研究设置高度复杂,未来多中心试验需考虑这一点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Tumor hypoxia is a major cause of resistance to radiochemotherapy in locally advanced head-and-neck cancer (LASCCHN). We present results of a randomized phase II trial on hypoxia dose escalation (DE) in LASCCHN based on dynamic [18F]FMISO (dynFMISO) positron emission tomography (PET). The purpose was to confirm the prognostic value of hypoxia PET and assess feasibility, toxicity and efficacy of hypoxia-DE. MATERIALS AND METHODS: Patients with LASCCHN underwent baseline dynFMISO PET/CT. Hypoxic volumes (HV) were derived from dynFMISO data. Patients with hypoxic tumors (HV > 0) were randomized into standard radiotherapy (ST: 70Gy/35fx) or dose escalation (DE: 77Gy/35fx) to the HV. Patients with non-hypoxic tumors were treated with ST. After a minimum follow-up of 2 years feasibility, acute/late toxicity and local control (LC) were analyzed. RESULTS: The study was closed prematurely due to slow accrual. Between 2009 and 2017, 53 patients were enrolled, 39 (74%) had hypoxic tumors and were randomized into ST or DE. For non-hypoxic patients, 100% 5-year LC was observed compared to 74% in patients with hypoxic tumors (p = 0.039). The difference in 5-year LC between DE (16/19) and ST (10/17) was 25%, p = 0.150. No relevant differences related to acute and late toxicities between the groups were observed. CONCLUSION: This study confirmed the prognostic value of hypoxia PET in LASCCHN for LC. Outcome after hypoxia DE appears promising and may support the concept of DE. Slow accrual and premature closure may partly be due to a high complexity of the study setup which needs to be considered for future multicenter trials.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Welz S, Paulsen F, Pfannenberg C, et al. Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT. Radiother Oncol. 2022. PMID: 35395276. doi:10.1016/j.radonc.2022.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。